UBS Group’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $191M | Buy |
|
|||||
|
2025
Q2 | $166M | Buy |
|
|||||
|
2025
Q1 | $126M | Sell |
|
|||||
|
2024
Q4 | $252M | Buy |
|
|||||
|
2024
Q3 | $137M | Sell |
|
|||||
|
2024
Q2 | $143M | Sell |
|
|||||
|
2024
Q1 | $128M | Sell |
|
|||||
|
2023
Q4 | $160M | Buy |
|
|||||
|
2023
Q3 | $133M | Buy |
|
|||||
|
2023
Q2 | $128M | Buy |
|
|||||
|
2023
Q1 | $104M | Buy |
|
|||||
|
2022
Q4 | $97.3M | Buy |
|
|||||
|
2022
Q3 | $62.3M | Buy |
|
|||||
|
2022
Q2 | $65.5M | Sell |
|
|||||
|
2022
Q1 | $76.5M | Buy |
|
|||||
|
2021
Q4 | $56.9M | Sell |
|
|||||
|
2021
Q3 | $59.6M | Buy |
|
|||||
|
2021
Q2 | $54M | Buy |
|
|||||
|
2021
Q1 | $43.1M | Sell |
|
|||||
|
2020
Q4 | $44.4M | Buy |
|
|||||
|
2020
Q3 | $45.6M | Sell |
|
|||||
|
2020
Q2 | $45M | Sell |
|
|||||
|
2020
Q1 | $41M | Sell |
|
|||||
|
2019
Q4 | $60.6M | Sell |
|
|||||
|
2019
Q3 | $56.4M | Sell |
|
|||||
|
2019
Q2 | $57M | Sell |
|
|||||
|
2019
Q1 | $77.9M | Sell |
|
|||||
|
2018
Q4 | $80.7M | Sell |
|
|||||
|
2018
Q3 | $94.1M | Sell |
|
|||||
|
2018
Q2 | $94.8M | Sell |
|
|||||
|
2018
Q1 | $99.3M | Sell |
|
|||||
|
2017
Q4 | $101M | Sell |
|
|||||
|
2017
Q3 | $107M | Sell |
|
|||||
|
2017
Q2 | $112M | Sell |
|
|||||
|
2017
Q1 | $113M | Sell |
|
|||||
|
2016
Q4 | $99.3M | Buy |
|
|||||
|
2016
Q3 | $107M | Buy |
|
|||||
|
2016
Q2 | $96.3M | Buy |
|
|||||
|
2016
Q1 | $80.9M | Sell |
|
|||||
|
2015
Q4 | $101M | Sell |
|
|||||
|
2015
Q3 | $101M | Sell |
|
|||||
|
2015
Q2 | $103M | Sell |
|
|||||
|
2015
Q1 | $114M | Sell |
|
|||||
|
2014
Q4 | $119M | Buy |
|